You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 294 No. 19, November 16, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Nutritional and Metabolic Disorders
 •Metabolism
 •Hypertension
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Arginine Metabolism, Pulmonary Hypertension, and Sickle Cell Disease

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The study by Dr Morris and colleagues1 indicates that a reduction in arginine availability may play a role in pulmonary hypertension and mortality in patients with SCD. The authors provide evidence that in these patients, hemolysis increases circulating levels of arginase, explaining the decline in plasma arginine and the increase in plasma ornithine levels. This derangement in arginine metabolism is associated with pulmonary hypertension and with mortality in patients with SCD. L-Arginine is the precursor of NO, and a reduction in its plasma levels could explain the endothelial vasodilator dysfunction and pulmonary hypertension that occurs in these patients.

However, there are 2 other potential causal explanations to consider. First, hemolysis also increases plasma levels of free hemoglobin. Hemoglobin is a potent scavenger of NO and may cause vasoconstriction.2 Second, there may be a contribution from endogenous inhibitors of NO synthase. Asymmetric dimethylarginine (ADMA) and N-monomethylarginine . . . [Full Text of this Article]

Jan T. Kielstein, MD
kielstein@yahoo.com

John P. Cooke, MD, PhD
Division of Cardiovascular Medicine
Stanford University School of Medicine
Stanford, Calif



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Arginine Metabolism, Pulmonary Hypertension, and Sickle Cell Disease
William H. Waugh
JAMA. 2005;294(19):2432-2433.
EXTRACT | FULL TEXT  

Arginine Metabolism, Pulmonary Hypertension, and Sickle Cell Disease—Reply
Claudia R. Morris, Elliott P. Vichinsky, Gregory J. Kato, Mark T. Gladwin, Stanley Hazen, and Sidney M. Morris, Jr
JAMA. 2005;294(19):2433-2434.
EXTRACT | FULL TEXT  

Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease
Claudia R. Morris, Gregory J. Kato, Mirjana Poljakovic, Xunde Wang, William C. Blackwelder, Vandana Sachdev, Stanley L. Hazen, Elliott P. Vichinsky, Sidney M. Morris, Jr, and Mark T. Gladwin
JAMA. 2005;294(1):81-90.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.